CellCentric raises $120M to treat multiple myeloma with capsule
CellCentric has raised a $120 million Series C round to support a potential accelerated approval in multiple myeloma, the UK biotech exclusively told Endpoints News. The company, more than two decades in the making, will ...
CellCentric has raised a $120 million Series C round to support a potential accelerated approval in multiple myeloma, the UK biotech exclusively told Endpoints News.
The company, more than two decades in the making, will ...
